ziprasidone has been researched along with Cognition Disorders in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (60.87) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rossi, A; Stratta, P | 1 |
| Li, CH; Rao, SZ; Shi, L; Zhan, GL; Zhang, H | 1 |
| Buckley, PF | 1 |
| Chen, X; Liu, ZX; Song, Y; Tang, MQ; Yuan, W; Zhang, ZH | 1 |
| Harvey, PD; Kremer, CM; Lombardo, I; Pappadopulos, E | 1 |
| Ayesa, R; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pérez-Iglesias, R; Ramirez-Bonilla, M; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL | 1 |
| Goldberg, TE; Gomar, JJ | 1 |
| Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Salden, ME; Sitskoorn, MM; van Veelen, NM; Verkes, RJ | 1 |
| Cucchiaro, J; Harvey, PD; Keefe, RS; Loebel, A; Ogasa, M | 1 |
| Bies, RR; Keefe, RS; Mamo, DC; Mimura, M; Pollock, BG; Rajji, TK; Sakurai, H; Stroup, ST; Suzuki, T; Uchida, H; Watanabe, K | 1 |
| Bitter, I; Bucci, P; Fleischhacker, WW; Galderisi, S; Kahn, RS; Libiger, J; Mucci, A | 1 |
| Agid, O; Pappadopulos, E; Remington, G; Siu, CO; Vanderburg, D | 1 |
| Abdul-Monim, Z; Neill, JC; Reynolds, GP | 1 |
| Harvey, PD | 1 |
| Christensen, JD; Garver, DL; Holcomb, JA | 1 |
| Bowie, CR; Harvey, PD; Loebel, A | 1 |
| Bowie, C; Green, MF; Harvey, PD; Loebel, A | 1 |
| Bates, JA; Burdick, KE; Kane, JM; Malhotra, AK; Razi, K; Sanders, M | 1 |
| Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG | 1 |
| Bowie, CR; Buckley, PF; Harvey, PD; Loebel, A | 1 |
| Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Goodman, C; Silver, H | 1 |
| Bilder, RM; Galluzzo, A; Gorini, B; Harvey, PD; Loebel, AD; Romeo, F; Sacchetti, E | 1 |
13 trial(s) available for ziprasidone and Cognition Disorders
| Article | Year |
|---|---|
A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Triglycerides | 2013 |
Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Chi-Square Distribution; Cognition Disorders; Double-Blind Method; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Sulpiride; Thiazoles | 2009 |
Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quality of Life; Schizophrenia; Statistics as Topic; Thiazoles; Verbal Learning; Young Adult | 2010 |
Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Interview, Psychological; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Young Adult | 2011 |
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dopamine D2 Receptor Antagonists; Female; Humans; Linear Models; Male; Middle Aged; Olanzapine; Piperazines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Young Adult | 2013 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Psychomotor Disorders; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Early prediction of clinical and functional outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Double-Blind Method; Drug Monitoring; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Models, Biological; Olanzapine; Patient Dropouts; Piperazines; Prognosis; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Weight Gain | 2013 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Nerve Growth Factors; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2005 |
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Patient Admission; Piperazines; Psychometrics; Psychotic Disorders; Schizophrenia; Thiazoles | 2006 |
Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cognition; Cognition Disorders; Female; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Piperazines; Schizophrenia; Severity of Illness Index; Thiazoles | 2006 |
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2007 |
A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; Drug Resistance; Drug Tolerance; Female; Humans; Italy; Male; Memory Disorders; Neuropsychological Tests; Piperazines; Placebos; Schizophrenia; Schizophrenic Psychology; Thiazoles; Trail Making Test; Treatment Outcome | 2008 |
10 other study(ies) available for ziprasidone and Cognition Disorders
| Article | Year |
|---|---|
Short-term remission in schizophrenia as a combination of several outcome measures.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Mass Index; Cognition Disorders; Female; Humans; Logistic Models; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Psychiatric Status Rating Scales; Recurrence; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Update on putative novel antipsychotics.
Topics: Antipsychotic Agents; Brain Injuries; Clozapine; Cognition Disorders; Drug Therapy, Combination; Employment, Supported; Humans; Piperazines; Schizophrenia; Thiazoles | 2014 |
A paired case-control comparison of ziprasidone on visual sustained attention and visual selective attention in patients with paranoid schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Cognition Disorders; Female; Healthy Volunteers; Humans; Male; Middle Aged; Piperazines; Schizophrenia, Paranoid; Thiazoles; Young Adult | 2015 |
Targeting cognition in schizophrenia research: from etiology to treatment.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dibenzothiazepines; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Reaction Time; Schizophrenia; Sulpiride; Thiazoles | 2009 |
The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition Disorders; Excitatory Amino Acid Antagonists; Female; Haloperidol; Injections, Intraperitoneal; Phencyclidine; Piperazines; Rats; Reversal Learning; Social Isolation; Thiazoles | 2003 |
Ziprasidone and cognition: the evolving story.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2003 |
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles | 2006 |
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Humans; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Remission Induction; Risperidone; Schizophrenia; Thiazoles | 2007 |
Impairment in error monitoring predicts poor executive function in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Memory, Short-Term; Neuropsychological Tests; Olanzapine; Piperazines; Reaction Time; Risperidone; Schizophrenia; Self Efficacy; Severity of Illness Index; Thiazoles | 2007 |